D-2-Hydroxyglutarate in Glioma Biology
Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an “oncometabolite”, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglu...
Main Authors: | Fu-Ju Chou, Yang Liu, Fengchao Lang, Chunzhang Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/9/2345 |
Similar Items
-
Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient’s selection
by: Lidia Gatto, et al.
Published: (2024-01-01) -
Sphingolipid Pathway as a Source of Vulnerability in IDH1<i><sup>mut</sup></i> Glioma
by: Tyrone Dowdy, et al.
Published: (2020-10-01) -
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
by: Yang Liu, et al.
Published: (2020-08-01) -
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
by: Victor Ruiz-Rodado, et al.
Published: (2020-06-01) -
Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI
by: Yongjian Sha, et al.
Published: (2023-02-01)